Effect of glucose or fat challenge on aspirin resistance in diabetes

Hussein N. Yassine, Grace Davis-Gorman, Craig S. Stump, Stephen S. Thomson, Justin Peterson, Paul F. McDonagh

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Aspirin has lower antiplatelet activity in diabetic patients. Our aim is to study the roles of acute hyperglycemia and hyperlipidemia on aspirin function in diabetic subjects with and without cardiovascular disease. Using urine thromboxane (pg/mg creatinine) and VerifyNow (Aspirin Resistance Measures-ARU), we investigated diabetic subjects during a 2-hour glucose challenge (n = 49) or a 4-hour fat challenge (n = 11). All subjects were currently taking aspirin (81 or 325mg). After fat ingestion, urine thromboxane increased in all subjects (Mean ± SE before: after) (1209 ± 336: 1552 ± 371, P =.01), while we noted a trend increase in VerifyNow measures (408 ± 8: 431 ± 18, P =.1). The response to glucose ingestion was variable. Diabetic subjects with cardiac disease and dyslipidemia increased thromboxane (1693 ± 364: 2799 ± 513, P <.05) and VerifyNow (457.6 ± 22.3: 527.1 ± 25.8, P <.05) measures after glucose. We conclude that saturated fat ingestion increases in vivo thromboxane production despite aspirin therapy.

Original languageEnglish (US)
Article number820876
JournalInternational Journal of Endocrinology
StatePublished - 2010

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems


Dive into the research topics of 'Effect of glucose or fat challenge on aspirin resistance in diabetes'. Together they form a unique fingerprint.

Cite this